Pulmonary function tests in connective tissue disease

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 4, 2007, Pages 379-388

  Wells, Athol U ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Pulmonary fibrosis; Pulmonary function tests; Pulmonary hypertension

Indexed keywords

BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; CARDIOPULMONARY EXERCISE TEST; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIAGNOSTIC VALUE; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG COMPLICATION; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG HEMORRHAGE; ORGANIZING PNEUMONIA; PATIENT MONITORING; PATIENT SELECTION; PLEURA DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; BLOOD GAS ANALYSIS; EXERCISE TEST; HOSPITALIZATION; LUNG DISEASE; PATHOPHYSIOLOGY; REST;

BLOOD GAS ANALYSIS; CONNECTIVE TISSUE DISEASES; EXERCISE TEST; HUMANS; LUNG DISEASES; PROGNOSIS; RESPIRATORY FUNCTION TESTS; REST; SEVERITY OF ILLNESS INDEX;

EID: 35848931683     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985610     Document Type: Review

References (48)

1. Gibson GJ. Clinical Tests of Respiratory Function. London: Chappell and Hall; 1996:223-224
2. Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997;155:1657-1664
3. Cordier J-F. Organising pneumonia. Thorax 2000;55:318-328
4. Burke CM, Glanville AR, Morris AJ, et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987; 42:131-135
5. Lipscomb DJ, Patel K, Hughes JM. Interpretation of increases in the transfer coefficient for carbon monoxide (TLCO/VA or KCO). Thorax 1978;33:728-733
6. Broderick A, Fuortes LJ, Merchant JA, Galvin JR, Shwartz DA. Pleural determinants of restrictive lung function and respiratory symptoms in an asbestos-exposed population. Chest 1992;101:684-691
7. Wright PH, Hansen A, Kreel L, Capel LH. Respiratory function changes after asbestos pleurisy. Thorax 1980;35: 31-36
8. Gibson GJ, Pride NB, Newsom-Davis J, Loh LC. Pulmonary mechanics in patients with respiratory muscle weakness. Am Rev Respir Dis 1977;115:389-395
9. Vincken WG, Elleker MG, Cosio MG. Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders. Am J Med 1987;83:673-680
10. Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983;38:616-623
11. Gould GA, Redpath AT, Ryan M, et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J 1991;4:141-146
12. Hansell DM, Rubens MB, Padley SPG, Wells AU. Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation. Radiology 1997; 203:721-726
13. Alton E, Turner-Warwick M. Lung involvement in scleroderma. In: Jayson MIV, Black CM, eds. Systemic Sclerosis: Scleroderma. London: John Wiley & Sons; 1988:181-205
14. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001;56: 622-627
15. Roschmann RA, Rothenberg RJ. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy [review]. Semin Arthritis Rheum 1987;16:174-185
16. Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pastural U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998;25: 1336-1343
17. Quanjer PH. Predicted values: how should we use them? Thorax 1988;43:663-664
18. Keogh BA, Crystal RG. Pulmonary function testing in interstitial pulmonary disease: what does it tell us?. Chest 1980;78:856-865
19. Peters-Golden M, Wise RA, Hochberg MC, Stevens MB, Wigley FM. Carbon monoxide diffusing capacity as a predictor of outcome in systemic sclerosis. Am J Med 1984; 77:1027-1034
20. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-150
21. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-1289
22. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994;149:1583-1590
23. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47:614-622
24. Staples CA, Muller NL, Vedal S, Abboud R, Ostrow DN, Miller RR. Usual interstitial pneumonia: correlation of CT with clinical, functional and radiologic findings. Radiology 1987;162:377-381
25. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin section computed tomography. Am J Respir Crit Care Med 1997;155:1367-1375
26. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed on computed tomography. Am J Respir Crit Care Med 2003;167:962-969
27. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997;40:1229-1236
28. Strickland NH, Hughes JM, Hart DA, Myers MJ, Lavender JP. Cause of regional ventilation-perfusion mismatching in patients with idiopathic pulmonary fibrosis: a combined CT and scintigraphic study. AJR Am J Roentgenol 1993;161: 719-725
29. Tashkin DP, Elashoff R, Clements PJet alfor the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666
30. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003;15:748-755
31. Steen V. Predictors of end stage lung disease in systemic sclerosis [editorial]. Ann Rheum Dis 2003;62:97-99
32. Cosgrove GP, Brown KK, Schiemann WP, Seris AE, Parr JE, Geraci MW. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004;170:242-251
33. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133:97-103
34. King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-1181
35. Marciniuk DD, Gallagher CG. Clinical exercise testing in interstitial lung disease. Clin Chest Med 1994;15:287-303
36. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084-1090
37. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:1150-1157
38. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103
39. Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007;66:169-173
40. Hyland RH, Gordon DA, Broder I, et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J Rheumatol 1983;10:395-405
41. Hebert CA, Byrnes TJ, Boethge BA, et al. Exercise limitation in patients with polymyositis. Chest 1990;98: 352-357
42. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007;131:657-663
43. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765-770
44. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537
45. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542
46. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-548
47. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664
48. Bouros D, Wells AU, Nicholson AG, et al. Histopathological subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-1586